

**SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP49152/2023 (Lineage HV.1)**

**Catalog No. NR-59703**

**Product Description:**

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD-HP49152/2023 was isolated from a human nasopharyngeal swab in Maryland, USA, in 2023. NR-59703 lot 70065499 was produced by infecting *Chlorocebus* (formerly *Cercopithecus*) *aethiops* (*C. aethiops*) kidney epithelial cells expressing transmembrane protease, serine 2 and human angiotensin-converting enzyme 2 (Vero E6-TMPRSS2-T2A-ACE2; VTA; BEI Resources NR-54970) with the deposited material and incubating in Eagle's Minimum Essential Medium containing Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate (ATCC® 30-2003™), supplemented with 2% fetal bovine serum (ATCC® 30-2020™) for 3 days at 37°C with 5% CO<sub>2</sub>. The cells and supernatant were spin-clarified at 1500 × g for 10 minutes at 4°C.

**Passage History:**

VT(2)/VTA(1) (Johns Hopkins University/BEI Resources); VT = *C. aethiops* kidney cells expressing transmembrane protease, serine 2 gene; VTA = *C. aethiops* kidney cells expressing transmembrane protease, serine 2 gene and human angiotensin-converting enzyme 2 (Vero E6-TMPRSS2-T2A-ACE2)

**Lot: 70065499**

**Manufacturing Date: 24JAN2024**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: [Contact@BEIResources.org](mailto:Contact@BEIResources.org). We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
<b>Identification by Infectivity in VTA Cells</b>	Cell rounding and detachment	Cell rounding and detachment
<b>Next-Generation Sequencing (NGS) of Complete Genome Using Illumina® MiSeq™ Platform</b> (Refer to Appendix I for NGS information)	≥ 98% identity with isolate hCoV-19/USA/MD-HP49152/2023 (EPI_ISL_18432261)	99.98% identity with isolate hCoV-19/USA/MD-HP49152/2023 (EPI_ISL_18432261)
<b>Titer by TCID<sub>50</sub> Assay in VTA Cells by Cytopathic Effect<sup>1,2</sup></b> (7 days at 37°C and 5% CO <sub>2</sub> )	Report results	4.6 × 10 <sup>4</sup> TCID <sub>50</sub> per mL
<b>Sterility (21-day incubation)</b> Harpo's HTYE broth, 37°C and 26°C, aerobic <sup>3</sup> Trypticase Soy broth, 37°C and 26°C, aerobic Sabouraud broth, 37°C and 26°C, aerobic Blood agar, 37°C, aerobic Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic DMEM with 10% FBS, 37°C and 5% CO <sub>2</sub>	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
<b>Mycoplasma Contamination</b> Agar and broth culture (14-day incubation at 37°C) DNA detection by PCR of extracted Test Article nucleic acid	None detected None detected	None detected None detected

<sup>1</sup>The Tissue Culture Infectious Dose 50% (TCID<sub>50</sub>) endpoint is the 50% infectious endpoint in cell culture. The TCID<sub>50</sub> is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD<sub>50</sub>) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID<sub>50</sub> provides a measure of the titer (or infectivity) of a virus preparation.

<sup>2</sup>Titer was determined by cytopathic effects (CPE) and completed in quadruplicate (5.0 × 10<sup>4</sup> per mL, 1.6 × 10<sup>4</sup> per mL, 8.9 × 10<sup>4</sup> per mL and 2.8 × 10<sup>4</sup> per mL). The average of the four values is reported.

<sup>3</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

16 APR 2023

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.



**APPENDIX I: NGS Information for NR-59703 lot 70065499**

Sequence analysis using AMGP readsQC-illumina.py pipeline and variant caller LoFreq version: 2.1.5 resulted in the discovery of seven SNPs and one DEL when compared to modified reference sequence GISAID EPI\_ISL\_18432261 (see Table I below). Additionally, both the modified reference sequence GISAID EPI\_ISL\_18432261 and NR-59703 lot 70065499 contained one hundred four SNPs, and six DELs when compared to GenBank MN908947 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome) (see Table II below). Quality scores over 60 indicate it is improbable that the variant call is incorrect.

**Table I: Variants with different nucleotides between NR-59703 lot 70065499 and reference sequence GISAID EPI\_ISL\_18432261**

Variant Type	Variant Position and Identified Alternative Base	Coverage	Length of Variant	Frequency of Variant	Gene (Region)	Amino Acid Mutation
SNP	t11522g	387	1	46.5116%	ORF1ab (nsp 6)	F184V
SNP	t13542g	206	1	5.3398%	ORF1ab (nsp 12)	Silent mutation
SNP	t14679c	342	1	6.7251%	ORF1ab (nsp 12)	Silent mutation
SNP	g18520t	508	1	12.2047%	ORF1ab (nsp 14)	V161L
SNP	t22114a	254	1	9.0551%	Spike	Silent mutation
SNP	t22114c	254	1	9.0551%	Spike	Silent mutation
DEL	Δ26284- 26286	718	-3	5.7103%	Envelope	ΔV14
SNP	a26530g	327	1	15.9021%	Membrane	D3G

**Table II: Variants with different nucleotides between NR-59703 lot 70065499 and GenBank MN908947.3 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome)**

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	t670g	N/A	1	100.0000%	ORF1ab (nsp1)	S135R
SNP	c2334t	N/A	1	100.0000%	ORF1ab (nsp2)	A510V
SNP	c2790t	N/A	1	100.0000%	ORF1ab (nsp3)	T24I
SNP	c3037t	N/A	1	100.0000%	ORF1ab (nsp3)	Silent mutation
SNP	g4184a	N/A	1	100.0000%	ORF1ab (nsp3)	G489S
SNP	c4321t	N/A	1	100.0000%	ORF1ab (nsp3)	Silent mutation
SNP	g5720a	N/A	1	100.0000%	ORF1ab (nsp3)	G1001S
SNP	c5835t	N/A	1	100.0000%	ORF1ab (nsp3)	S1039L
SNP	c9344t	N/A	1	100.0000%	ORF1ab (nsp4)	L264F

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	a9424g	N/A	1	100.0000%	ORF1ab (nsp4)	Silent mutation
SNP	c9534t	N/A	1	100.0000%	ORF1ab (nsp4)	T327I
SNP	c9693t	N/A	1	100.0000%	ORF1ab (nsp4)	A380V
SNP	c9866t	N/A	1	100.0000%	ORF1ab (nsp4)	L438F
SNP	c10029t	N/A	1	100.0000%	ORF1ab (nsp4)	T492I
SNP	c10198t	N/A	1	100.0000%	ORF1ab (nsp5)	Silent mutation
SNP	g10447a	N/A	1	100.0000%	ORF1ab (nsp5)	Silent mutation
SNP	c10449a	N/A	1	100.0000%	ORF1ab (nsp5)	P132H
DEL	Δ11288-11296	N/A	-9	100.0000%	ORF1ab (nsp6)	ΔSGF (amino acids 106-108)
SNP	c12789t	N/A	1	100.0000%	ORF1ab (nsp9)	T35I
SNP	c12880t	N/A	1	100.0000%	ORF1ab (nsp9)	Silent mutation
SNP	c14408t	N/A	1	100.0000%	ORF1ab (nsp12)	P323L
SNP	g15451a	N/A	1	100.0000%	ORF1ab (nsp12)	G671S
SNP	c15714t	N/A	1	100.0000%	ORF1ab (nsp12)	Silent mutation
SNP	c15738t	N/A	1	100.0000%	ORF1ab (nsp12)	Silent mutation
SNP	t15939c	N/A	1	100.0000%	ORF1ab (nsp12)	Silent mutation
SNP	t16342c	N/A	1	100.0000%	ORF1ab (nsp13)	S36P
SNP	a16878t	N/A	1	100.0000%	ORF1ab (nsp13)	Silent mutation
SNP	c17410t	N/A	1	100.0000%	ORF1ab (nsp13)	R392C
SNP	t17859c	N/A	1	100.0000%	ORF1ab (nsp13)	Silent mutation
SNP	a18163g	N/A	1	100.0000%	ORF1ab (nsp14)	I42V
SNP	a18492g	N/A	1	100.0000%	ORF1ab (nsp14)	Silent mutation
SNP	a19326g	N/A	1	100.0000%	ORF1ab (nsp14)	Silent mutation
SNP	c19955t	N/A	1	100.0000%	ORF1ab (nsp15)	T112I
SNP	a20055g	N/A	1	100.0000%	ORF1ab (nsp15)	Silent mutation
SNP	c21618t	N/A	1	100.0000%	Spike	T19I
DEL	Δ21633-21641	N/A	-9	100.0000%	Spike	A27S ΔLPP (amino acids 24-26)
SNP	g21718t	N/A	1	100.0000%	Spike	Q52H
SNP	t21810c	N/A	1	100.0000%	Spike	V83A
SNP	g21987a	N/A	1	100.0000%	Spike	G142D
DEL	Δ21991-21993	N/A	-3	100.0000%	Spike	ΔY144
SNP	c22000a	N/A	1	100.0000%	Spike	H146Q
SNP	c22033a	N/A	1	100.0000%	Spike	F157L
SNP	c22109g	N/A	1	100.0000%	Spike	Q183E
SNP	t22200a	N/A	1	100.0000%	Spike	V213E
SNP	g22317t	N/A	1	100.0000%	Spike	G252V
SNP	c22480t	N/A	1	100.0000%	Spike	Silent mutation
SNP	g22577c	N/A	1	100.0000%	Spike	G339H

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	g22578a	N/A	1	100.0000%		
SNP	g22599c	N/A	1	100.0000%	Spike	R346T
SNP	c22664a	N/A	1	100.0000%	Spike	L368I
SNP	c22674t	N/A	1	100.0000%	Spike	S371F
SNP	t22679c	N/A	1	100.0000%	Spike	S373P
SNP	c22686t	N/A	1	100.0000%	Spike	S375F
SNP	a22688g	N/A	1	100.0000%	Spike	T376A
SNP	g22775a	N/A	1	100.0000%	Spike	D405N
SNP	a22786c	N/A	1	100.0000%	Spike	R408S
SNP	g22813t	N/A	1	100.0000%	Spike	K417N
SNP	t22882g	N/A	1	100.0000%	Spike	N440K
SNP	g22895c	N/A	1	100.0000%	Spike	V445P
SNP	t22896a	N/A	1	100.0000%		
SNP	g22898a	N/A	1	100.0000%	Spike	G446S
SNP	t22917g	N/A	1	100.0000%	Spike	L452R
SNP	t22930a	N/A	1	100.0000%	Spike	F456L
SNP	t22942g	N/A	1	100.0000%	Spike	N460K
SNP	g22992a	N/A	1	100.0000%	Spike	S477N
SNP	c22995a	N/A	1	100.0000%	Spike	T478K
SNP	a23013c	N/A	1	100.0000%	Spike	E484A
SNP	t23018c	N/A	1	100.0000%	Spike	F486P
SNP	t23019c	N/A	1	100.0000%		
SNP	t23031c	N/A	1	100.0000%	Spike	F490S
SNP	a23055g	N/A	1	100.0000%	Spike	Q498R
SNP	a23063t	N/A	1	100.0000%	Spike	N501Y
SNP	t23075c	N/A	1	100.0000%	Spike	Y505H
SNP	a23403g	N/A	1	100.0000%	Spike	D614G
SNP	c23525t	N/A	1	100.0000%	Spike	H655Y
SNP	A23539t	N/A	1	100.0000%	Spike	Silent mutation
SNP	t23599g	N/A	1	100.0000%	Spike	N679K
SNP	c23604a	N/A	1	100.0000%	Spike	P681R
SNP	c23854a	N/A	1	100.0000%	Spike	N764K
SNP	g23948t	N/A	1	100.0000%	Spike	D796Y
SNP	a24424t	N/A	1	100.0000%	Spike	Q954H
SNP	t24469a	N/A	1	100.0000%	Spike	N969K
SNP	c25000t	N/A	1	100.0000%	Spike	Silent mutation
SNP	c25416t	N/A	1	100.0000%	ORF3a	Silent mutation
SNP	c25584t	N/A	1	100.0000%	ORF3a	Silent mutation

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	c26060t	N/A	1	100.0000%	ORF3a	T223I
SNP	c26270t	N/A	1	100.0000%	Envelope	T9I
SNP	a26275g	N/A	1	100.0000%	Envelope	T11A
SNP	c26577g	N/A	1	100.0000%	Membrane	Q19E
SNP	g26709a	N/A	1	100.0000%	Membrane	A63T
SNP	c26858t	N/A	1	100.0000%	Membrane	Silent mutation
SNP	a27259c	N/A	1	100.0000%	ORF6	Silent mutation
SNP	g27382c	N/A	1	100.0000%	ORF6	D61L
SNP	a27383t	N/A	1	100.0000%		
SNP	t27384c	N/A	1	100.0000%		
SNP	a27507c	N/A	1	100.0000%	ORF7a	Silent mutation
SNP	c27807t	N/A	1	100.0000%	ORF7b	Silent mutation
SNP	g27915t	N/A	1	100.0000%	ORF8	G8stop <sup>2</sup>
SNP	a28271t	N/A	1	100.0000%	Intergenic (ORF8/ Nucleocapsid)	Untranslated
SNP	t28297c	N/A	1	100.0000%	Nucleocapsid	Silent mutation
SNP	c28311t	N/A	1	100.0000%	Nucleocapsid	P13L
DEL	Δ28362-28370	N/A	-9	100.0000%	Nucleocapsid	ΔERS (amino acids 31-33)
SNP	g28881a	N/A	1	100.0000%	Nucleocapsid	R203K
SNP	g28882a	N/A	1	100.0000%		
SNP	g28883c	N/A	1	100.0000%		
SNP	a29510c	N/A	1	100.0000%	Nucleocapsid	S413R
SNP	c29625t	N/A	1	100.0000%	ORF10	S23F
DEL	Δ29734-29759	N/A	-26	100.0000%	3'UTR	Untranslated
SNP	c29784t	N/A	1	100.0000%	3'UTR	Untranslated
DEL	Δ29902	N/A	-1	100.0000%	3'UTR	Untranslated

<sup>1</sup>Coverage for all variants in Table II is listed as 'N/A'. There is no read coverage information for these variants because the sample reads are only mapped to the reference sequence and not to the SARS-CoV-2, Wuhan-Hu-1 isolate sequence (GenBank MN908947), but that does not mean these areas lack for coverage. All variants in Table II are mismatches in between the reference sequence and the SARS-CoV-2, Wuhan-Hu-1 sequence, so these variants will be assigned a frequency of 100% and will therefore be majority SNPs.

<sup>2</sup>G8stop results in 94.2% truncation of the protein sequence.